Click here to view cell apoptosis assay products

Recombinant Human OX40/TNFRSF4 Protein (His & Fc Tag)(Active)

  • Cat.No.:PKSH031578

  • Expression host: HEK293 Cells

To Purchase PKSH031578

  • 50μg
  • 100μg
Price: $454


Synonyms Tumor necrosis factor receptor superfamily member 4;TNFRSF4;OX40;CD134;Txgp1;ACT35;IMD16;TXGP1L
Species Human
Expression_host HEK293 Cells
Sequence Met 1-Ala 216
Accession NP_003318.1
Application Functional ELISA
Mol_Mass 48.2 kDa
AP_Mol_Mass 68 kDa
Tag C-His & Fc
Bio_Activity Immobilized Cynomolgus mFc-TNFSF4 at 10 μg/ml (100 μl/well) can bind human TNFRSF4-Fch, The EC50 of human TNFRSF4-Fch is 0.23-0.55 μg/ml.


Purity > 85 % as determined by reducing SDS-PAGE.
Endotoxin level < 1.0 EU per µg as determined by the LAL method.
Storage Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping This product is provided as lyophilized powder which is shipped with ice packs.
Formulation Lyophilized from sterile PBS, pH 7.4
Reconstitution Please refer to the printed manual for detailed information.


OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.

Related Products


From now on, if you have published a paper by using any of our products since 1/1/2019, fill out the “Elabscience Publication Reward Application Form”carefully and send it to, we will get back to you with the reward after we confirm it ASAP!

View more details about our Publication Reward >>


  • Show all
  • Reviews
  • Q&A
... Show All Show Less

People Also Bought

Apply for
*Product Name:
*Catalog Number:
*When will you use it?